Restricting O-Linked Glycosylation of the Mucin-like Domains Enhances Immunogenicity and Protective Efficacy of a Respiratory Syncytial Virus G Glycoprotein Vaccine Antigen

<b>Background:</b> As of 2024, three approved respiratory syncytial virus (RSV) vaccines are licensed for use in adults in the United States: Arexvy™, Abrysvo™, and mRESVIA™. These vaccines are specifically designed to prevent lower respiratory tract disease caused by RSV in adults aged 60 and older...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sara M. O’Rourke, Jackelyn Murray, Maria G. Juarez, Ralph A. Tripp, Rebecca M. DuBois
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2025-09-01
Sarja:	Vaccines
Aiheet:	RSV vaccine recombinant RSV G<sup>ecto</sup> glycoprotein O-linked glycosylation immunogen
Linkit:	https://www.mdpi.com/2076-393X/13/10/1004
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!